About Novacyt
Novacyt is a publicly listed company based in Velizy-villacoublay (France) founded in 2005. Developer of cytology instruments and consumables for oncology and infectious disease. Novacyt has completed 4 acquisitions, including IT-IS, Lab21 and Primerdesign. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified.
Company details
Novacyt was founded in 2005 in Velizy Villacoublay, France, as a developer of cytology instruments and consumables focused on oncology and infectious disease sectors. Cellular diagnostics are emphasized through a portfolio of products and services for cancer and infectious disease applications. Operations center on proprietary platform technology NovaPrep, an automated liquid cytology instrument used for cancer diagnosis. The company operates primarily in the medical diagnostics industry.
- Headquarters Velizy-villacoublay, France
- Stage Public
- SectorsHealthcare
- Website novacyt.com
- Social LinkedIn
- Legal Name Novacyt Sas
- Annual Revenue$27.48 M (USD)0.86as on Dec 31, 2025
- Net Profit-$31.4 M (USD)45.83as on Dec 31, 2025
- EBITDA-$11.06 M (USD)11.51as on Dec 31, 2025
- Latest Funding Round$4.72M (USD), Debt – Conventional
May 2018
- InvestorsKreos Capital
& 1 more
- Investments & AcquisitionsIT-IS
& 3 more
Funding Insights of Novacyt
- Total Rounds 9
- Last Round Debt – Conventional — $4.72M
- First Round $3.83M
(Dec 2014)
- Investors Count 2
All 9 funding rounds of Novacyt with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2018 | $4.72M | Debt – Conventional | – | – | – |
| Oct 2017 | $11.76M | Post-IPO | – | – | – |
| Jun 2017 | $3.36M | Post-IPO | – | – | – |
| Jun 2016 | $1.56M | Post-IPO | – | – | – |
| May 2016 | $4.79M | Post-IPO | – | – | |
| Apr 2016 | $8.7M | Post-IPO | – | – | – |
| Aug 2015 | $5.48M | Post-IPO | – | – | – |
| Jul 2015 | $2.17M | Post-IPO | – | – | – |
| Dec 2014 | $3.83M | Post-IPO | – | – |
2 investors in total: 2 institutional.
Investors in Novacyt
Novacyt has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Kreos Capital and Eiffel Investment Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt is provided to growth-stage companies across multiple sectors. | 1998 | kreoscapital.com | London, United Kingdom | |
Private equity and private debt firm focused on multiple sector | eiffel-ig.com | Paris, France |
Investor details for Novacyt
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Novacyt
18 people are tracked at Novacyt (7 in leadership, 5 in board & advisors, 6 in team).
| Name | Role | Group |
|---|---|---|
Lyn Rees | Executive Director | Leadership |
Joanne Mason | Chief Scientific Officer | Leadership |
David Franks | Chief HR Officer | Leadership |
Roy Lam | Head Of Group Reporting | Leadership |
Steven Gibson | Chief Financial Officer | Leadership |
Maria Watters | Chief Commercial Officer (cco) | Leadership |
Vanessa Childs McIpd | Head Of Human Resources | Leadership |
Juliet Thompson | Non-Executive Director | Board & advisors |
Jean-Pierre Crinelli | Non-Executive Director | Board & advisors |
John Brown | Non-Executive Director | Board & advisors |
Andrew Heath | Non-Executive Director | Board & advisors |
James Wakefield | Non-Executive Director & Chairman | Board & advisors |
Kay Campbell | Human Resources Manager | Team |
Maike Schramm | Field Application Specialist | Team |
Sagar Vengurlekar | International Sales Manager - EMEA | Team |
Amber Davies | Group Financial Reporting Manager | Team |
Amanda Heron | Group Accounts Payable Manager | Team |
Ann-Marie Vinnicombe Acma | Finance Manager | Team |
Complete people profiles for Novacyt
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Novacyt
Novacyt is a publicly listed company on the EURONEXT with ticker symbol ALNOV in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Nov 2017
- Listed onLSE: NCYT
- Listed entityNovacyt SAS
- Exchange sectorHealth technology
- ISINFR0010397232
- Share price0.46 EUR (-1.07% on the day) · 2026-10-14
- Market capitalisation33,826,049.00 EUR
- EPS (diluted, trailing year)-0.36 EUR
- Volume (last session)7,700
Financials of Novacyt
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 23.4M EUR | -26.7M EUR | -9.4M EUR |
| 2024 | 23.2M EUR | -49.3M EUR | -10.6M EUR |
| 2023 | 12.2M EUR | -32.5M EUR | -13.7M EUR |
| 2022 | 24.7M EUR | -30.2M EUR | -16.5M EUR |
| 2021 | 107.8M EUR | -11.3M EUR | 44.9M EUR |
Detailed financial statements for Novacyt
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Novacyt
Novacyt has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include IT-IS, Lab21 and Primerdesign.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Clinical research, trials, and biomarker discovery services are offered. | yourgenehealth.com | Manchester, United Kingdom | 2013 | Jul 2023 | $21.41M | |
Data analytics and graphical user interface development services are provided. | itisint.com | Middlesbrough, United Kingdom | 2004 | Oct 2020 | $13.08M | |
Real-time PCR kits and reagents using its technology | primerdesign.co.uk | Southampton, United Kingdom | 2005 | Jan 2016 | $14.04M | |
Personalised diagnostic testing for diseases and predisposition is specialised in. | lab21.com | Cambridge, United Kingdom | 2005 | May 2014 | $34.1M |
Complete acquisition details for Novacyt
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Novacyt
8 dated milestones of Novacyt across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Novacyt is founded.
- Acquisition Acquires Lab21.
- Funding First funding round of $3.8M.
- Acquisition Acquires Primerdesign.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Debt – Conventional, of $4.7M.
- Acquisition Acquires IT-IS.
- Acquisition Acquires Yourgene Health.
Web traffic of Novacyt
The website of Novacyt (novacyt.com) receives about 8.7K visits a month.
- Monthly visits8.7K
▼ 5.5% vs previous month
Websites whose visitors overlap most with Novacyt. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
deinove.com | deinove.com | 100% | – | ||
google.fr | google.fr | 70% | #273 | – | |
secondhand-trailers.co.uk | secondhand-trailers.co.uk | 66% | #2,517,806 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Novacyt
Complete news archive for Novacyt
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novacyt
Novacyt was founded in 2005 and raised its 1st funding round 9 years after it was founded.
Novacyt is headquartered in Velizy-villacoublay, France. It is registered at Velizy-villacoublay, Ile-de-france, France.
Annual revenue of Novacyt is $27.48M as on Dec 31, 2025.
Novacyt was founded in 2005 in Velizy Villacoublay, France, as a developer of cytology instruments and consumables focused on oncology and infectious disease sectors. Cellular diagnostics are emphasized through a portfolio of products and services for cancer and infectious disease applications. Operations center on proprietary platform technology NovaPrep, an automated liquid cytology instrument used for cancer diagnosis. The company operates primarily in the medical diagnostics industry.
Yes, Novacyt is publicly traded on EURONEXT under the ticker symbol ALNOV.
Novacyt has made 4 acquisitions, including IT-IS, Lab21, and Primerdesign.
Novacyt has 2 investors. Key investors include Kreos Capital, and Eiffel Investment Group.